Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Peter Hartung

Showing results (1-10 of 601) with videos related to

Pageof 61
Sort By:
Journal of Neurology|September 20, 2008
Advances in the understanding of the mechanism of action of IVIgHans-Peter Hartung
Neurology(R) Neuroimmunology & Neuroinflammation|June 7, 2020
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MSHans-Peter Hartung,
Expert Opinion on Pharmacotherapy|February 25, 2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosisHans-Peter Hartung
Journal of Neurology|September 20, 2005
Early treatment and dose optimisation BENEFIT and BEYONDHans-Peter Hartung
Journal of Neurology|April 17, 2002
Chemotherapy-induced peripheral neuropathyStefan Quasthoff, Hans Peter Hartung
Annals of Neurology|October 31, 2007
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Bernhard Hemmer, Hans-Peter Hartung
Current Opinion in Neurology|March 27, 2025
Multiple sclerosis: advances and challenges in diagnosisSilvia Tenembaum, Hans-Peter Hartung
Clinical Neuropharmacology|January 12, 2010
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosisJerold Chun, Hans-Peter Hartung
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|July 21, 2020
Multiple sclerosis and COVID-19Jan Mares, Hans-Peter Hartung
Current Opinion in Neurology|March 26, 2025
Update on novel multiple sclerosis treatments: from dismal defeat to scintillating successBruce Cree, Hans-Peter Hartung
Pageof 61

Showing results (1-10 of 601) with videos related to

Sort By:
Pageof 61
Journal of Neurology|September 20, 2008
Advances in the understanding of the mechanism of action of IVIgHans-Peter Hartung
Neurology(R) Neuroimmunology & Neuroinflammation|June 7, 2020
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MSHans-Peter Hartung,
Expert Opinion on Pharmacotherapy|February 25, 2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosisHans-Peter Hartung
Journal of Neurology|September 20, 2005
Early treatment and dose optimisation BENEFIT and BEYONDHans-Peter Hartung
Journal of Neurology|April 17, 2002
Chemotherapy-induced peripheral neuropathyStefan Quasthoff, Hans Peter Hartung
Annals of Neurology|October 31, 2007
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Bernhard Hemmer, Hans-Peter Hartung
Current Opinion in Neurology|March 27, 2025
Multiple sclerosis: advances and challenges in diagnosisSilvia Tenembaum, Hans-Peter Hartung
Clinical Neuropharmacology|January 12, 2010
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosisJerold Chun, Hans-Peter Hartung
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|July 21, 2020
Multiple sclerosis and COVID-19Jan Mares, Hans-Peter Hartung
Current Opinion in Neurology|March 26, 2025
Update on novel multiple sclerosis treatments: from dismal defeat to scintillating successBruce Cree, Hans-Peter Hartung
Pageof 61